Sanofi (NYSE:SNY) Earns Market Perform Rating from Cowen and Company
Cowen and Company restated their market perform rating on shares of Sanofi (NYSE:SNY) in a research note issued to investors on Tuesday, August 1st. The brokerage currently has a $52.00 price target on the stock, up from their previous price target of $46.00.
A number of other equities analysts also recently commented on SNY. Berenberg Bank downgraded shares of Sanofi from a buy rating to a hold rating in a report on Thursday, May 11th. BidaskClub raised shares of Sanofi from a hold rating to a buy rating in a report on Friday, June 23rd. Zacks Investment Research raised shares of Sanofi from a hold rating to a buy rating and set a $55.00 price objective for the company in a report on Friday, June 2nd. Argus lifted their price objective on shares of Sanofi from $50.00 to $55.00 and gave the stock a buy rating in a report on Friday, June 9th. Finally, TheStreet raised shares of Sanofi from a c+ rating to a b- rating in a report on Monday, April 24th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $63.75.
Shares of Sanofi (NYSE:SNY) traded up 0.30% on Tuesday, reaching $47.55. 717,957 shares of the company traded hands. The company has a 50-day moving average of $47.99 and a 200-day moving average of $46.11. The stock has a market capitalization of $119.42 billion, a price-to-earnings ratio of 11.23 and a beta of 0.88. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.24.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.74. The business had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. Analysts anticipate that Sanofi will post $3.26 earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of SNY. Fisher Asset Management LLC boosted its stake in shares of Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after buying an additional 1,022,953 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock valued at $203,296,000 after buying an additional 815,820 shares during the period. Global Financial Private Capital LLC acquired a new stake in shares of Sanofi during the first quarter valued at approximately $35,034,000. BlackRock Inc. boosted its stake in shares of Sanofi by 47.6% in the second quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after buying an additional 720,523 shares during the period. Finally, Karp Capital Management Corp acquired a new stake in shares of Sanofi during the first quarter valued at approximately $26,174,000. 9.96% of the stock is owned by institutional investors and hedge funds.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.